Brainsway (BWAY)
NASDAQ:BWAY
Want to see BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
$15.81
-$0.11(-1.13%)
At close: 4:00 PM EST
$15.81
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$4.31 - $17.26
Previous CloseN/A
Volume9.67K
Average Volume (3M)185.96K
Market Cap
$694.13M
Enterprise Value$633.49M
Total Cash (Recent Filing)$69.13M
Total Debt (Recent Filing)$6.82M
Price to Earnings (P/E)14.8
Beta1.44
Next Earnings
May 13, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding40,037,530
10 Day Avg. Volume177,700
30 Day Avg. Volume185,964
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.48
Price to Sales (P/S)3.45
P/FCF Ratio11.06
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue12.11
Enterprise Value/Gross Profit16.06
Enterprise Value/Ebitda63.30
Forecast
1Y Price Target
$15.00Price Target Upside-5.12% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.18
Revenue Forecast (FY)$66.43M
Bulls Say, Bears Say
Bulls Say
Shift To Recurring Revenue Via Multi-year Leases And Growing Installed BaseMoving to multi-year leases and a >1,700-site installed base materially raises revenue visibility and stickiness. Durable recurring revenue drives higher lifetime value, supports predictable service and consumable sales, and enables operating leverage that can sustain margin expansion over multiple years.
Consistently High Gross Margins (~74–78%)Sustained mid‑70s gross margins create durable economic upside: they provide scope to absorb SG&A and R&D while maintaining profitability, increase incremental cash conversion on additional volume, and underpin the company’s ability to scale EBITDA as recurring revenues grow.
Conservative Balance Sheet With Low Leverage And Solid Equity BaseA conservatively financed balance sheet with minimal leverage and growing assets provides strategic optionality: it supports M&A or milestone investments, funds partnerships and commercialization efforts without distress, and reduces refinancing risk during demand variability.
Bears Say
Volatile Cash Flow And Recent Free Cash Flow DeclineDespite stronger recent cash generation, historical swings and a YoY FCF decline indicate sensitivity to working‑capital movements and investment timing. This volatility can constrain reinvestment pacing, complicate multi-year planning, and increase reliance on prudent cash management for growth.
Profitability Is Recent After Multi-year Losses; Margin VariabilityThe earnings turnaround is meaningful but recent; historical losses and fluctuating margins show operating performance can reverse if growth or reimbursement weakens. Sustaining margins will require consistent utilization and disciplined cost control amid competitive or reimbursement shifts.
Revenue Growth Dependent On Reimbursement And Provider AdoptionLong‑term growth hinges on payer policies and clinic adoption. While recent payer wins help, reimbursement changes or slow clinic uptake would directly limit system placements and recurring consumable/service revenue, making topline and installed‑base expansion contingent on external policy and provider behavior.
Brainsway News
BWAY FAQ
What was Brainsway’s price range in the past 12 months?
Brainsway lowest stock price was $4.30 and its highest was $17.26 in the past 12 months.
What is Brainsway’s market cap?
Brainsway’s market cap is $694.13M.
When is Brainsway’s upcoming earnings report date?
Brainsway’s upcoming earnings report date is May 13, 2026 which is in 3 days.
How were Brainsway’s earnings last quarter?
Brainsway released its earnings results on Mar 11, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.039.
Is Brainsway overvalued?
According to Wall Street analysts Brainsway’s price is currently Overvalued.
Does Brainsway pay dividends?
Brainsway does not currently pay dividends.
What is Brainsway’s EPS estimate?
Brainsway’s EPS estimate is 0.03.
How many shares outstanding does Brainsway have?
Brainsway has 40,037,530 shares outstanding.
What happened to Brainsway’s price movement after its last earnings report?
Brainsway reported an EPS of $0.07 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 8.34%.
Which hedge fund is a major shareholder of Brainsway?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (-5.12% Downside)
$15.00 (-5.12% Downside)
Blogger Sentiment
Bullish
BWAY Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 254.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
283.73%
12-Months-Change
Fundamentals
Return on Equity
11.10%
Trailing 12-Months
Asset Growth
20.01%
Trailing 12-Months
Company Description
Brainsway
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Company Deck
BWAY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
BrainsWay's Q3 2025 earnings call indicated strong growth and positive developments, including record revenue, increased system shipments, and successful strategic investments. Despite increased operating expenses and a delay in FDA clearance for Neurolief, the company's performance and raised guidance reflect a generally optimistic outlook.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$15.00
▼(-5.12% Downside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
―
Insiders
0.46% Mutual Funds
1.31% Other Institutional Investors
97.76% Public Companies and
Individual Investors